Literature DB >> 30218651

Optogenetic approaches to vision restoration.

M P Simunovic1, W Shen2, J Y Lin3, D A Protti4, L Lisowski5, M C Gillies6.   

Abstract

Inherited retinal disease (IRD) affects about 1 in 3000 to 1 in 5000 individuals and is now believed to be the most common cause of blindness registration in developed countries. Until recently, the management of such conditions had been exclusively supportive. However, advances in molecular biology and medical engineering have now seen the rise of a variety of approaches to restore vision in patients with IRDs. Optogenetic approaches are primarily aimed at rendering secondary and tertiary neurons of the retina light-sensitive in order to replace degenerate or dysfunctional photoreceptors. Such approaches are attractive because they provide a "causative gene-independent" strategy, which may prove suitable for a variety of patients with IRD. We discuss theoretical and practical considerations in the selection of optogenetic molecules, vectors, surgical approaches and review previous trials of optogenetics for vision restoration. Optogenetic approaches to vision restoration have yielded promising results in pre-clinical trials and a phase I/II clinical trial is currently underway (ClinicalTrials.gov NCT02556736). Despite the significant inroads made in recent years, the ideal optogenetic molecule, vector and surgical approach have yet to be established.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Gene therapy; Inherited retinal disease; Optogenetics; Retinitis pigmentosa; Vision restoration

Mesh:

Year:  2018        PMID: 30218651     DOI: 10.1016/j.exer.2018.09.003

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  29 in total

1.  Improved CoChR Variants Restore Visual Acuity and Contrast Sensitivity in a Mouse Model of Blindness under Ambient Light Conditions.

Authors:  Tushar H Ganjawala; Qi Lu; Mitchell D Fenner; Gary W Abrams; Zhuo-Hua Pan
Journal:  Mol Ther       Date:  2019-04-09       Impact factor: 11.454

Review 2.  Molecular Biology of Microbial Rhodopsins.

Authors:  Martin Engelhard
Journal:  Methods Mol Biol       Date:  2022

Review 3.  Development of Stem Cell Therapies for Retinal Degeneration.

Authors:  Emma L West; Joana Ribeiro; Robin R Ali
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-08-03       Impact factor: 9.708

4.  A new approach to urinary bladder control with optogenetics.

Authors:  Eunkyoung Park; Kyu-Sung Lee
Journal:  Investig Clin Urol       Date:  2019-02-27

Review 5.  Has retinal gene therapy come of age? From bench to bedside and back to bench.

Authors:  Ivana Trapani; Alberto Auricchio
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 6.150

Review 6.  Molecular Therapies for Inherited Retinal Diseases-Current Standing, Opportunities and Challenges.

Authors:  Irene Vázquez-Domínguez; Alejandro Garanto; Rob W J Collin
Journal:  Genes (Basel)       Date:  2019-08-28       Impact factor: 4.096

7.  Autosomal Dominant Retinitis Pigmentosa Due to Class B Rhodopsin Mutations: An Objective Outcome for Future Treatment Trials.

Authors:  Alexander Sumaroka; Artur V Cideciyan; Jason Charng; Vivian Wu; Christian A Powers; Bhavya S Iyer; Brianna Lisi; Malgorzata Swider; Samuel G Jacobson
Journal:  Int J Mol Sci       Date:  2019-10-27       Impact factor: 5.923

Review 8.  Molecular Therapies for Choroideremia.

Authors:  Jasmina Cehajic Kapetanovic; Alun R Barnard; Robert E MacLaren
Journal:  Genes (Basel)       Date:  2019-09-23       Impact factor: 4.096

9.  Comparison of AAV-Mediated Optogenetic Vision Restoration between Retinal Ganglion Cell Expression and ON Bipolar Cell Targeting.

Authors:  Qi Lu; Tushar H Ganjawala; Andrea Krstevski; Gary W Abrams; Zhuo-Hua Pan
Journal:  Mol Ther Methods Clin Dev       Date:  2020-05-22       Impact factor: 6.698

Review 10.  Retinal Dystrophies and the Road to Treatment: Clinical Requirements and Considerations.

Authors:  Mays Talib; Camiel J F Boon
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2020 May-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.